title: Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies.
abstract: Radiotherapy is the primary treatment of nasopharyngeal carcinoma and combination chemotherapy can enhance treatment outcomes for locoregionally advanced disease. The Intergroup 0099 study using concurrent-adjuvant cisplatin-based chemoradiotherapy was the first trial to demonstrate a survival benefit. Since then, there have been attempts to further improve the treatment results by altering the chemotherapy sequence, using different chemotherapeutic agents or schedules, and extending the use of chemotherapy to early-stage disease. This review provides an overview of the data and highlights the current controversies behind international guidelines.
authors.affiliation: Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China; Department of Clinical Oncology, The University of Hong Kong - Shenzhen Hospital, 1 Haiyuan First Road, Futian District, Shenzhen, Guangdong 518053, China.
authors.forename: Henry
authors.initials: H
authors.lastname: Sze
authors.affiliation: Department of Radiation Oncology, Research in Epidemiology and Population Health, INSERM U1018, Paris-Saclay University, Gustave-Roussy, 114 rue Edouard Vaillant, 94 805 Villejuif Cedex, France. Electronic address: annelee@hku-szh.org.
authors.forename: Pierre
authors.initials: P
authors.lastname: Blanchard
authors.affiliation: Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lock Man Road, Chai Wan, Hong Kong, China.
authors.forename: Wai Tong
authors.initials: WT
authors.lastname: Ng
authors.affiliation: Department of Biostatistics and Epidemiology, Ligue National Contre le Cancer Platform of Meta-analyses in Oncology, Research in Epidemiology and Population Health, INSERM U1018, Paris-Saclay University, Gustave-Roussy, 114 rue Edouard Vaillant, 94 805 Villejuif Cedex, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Pignon
authors.affiliation: Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China; Department of Clinical Oncology, The University of Hong Kong - Shenzhen Hospital, 1 Haiyuan First Road, Futian District, Shenzhen, Guangdong 518053, China.
authors.forename: Anne W M
authors.initials: AW
authors.lastname: Lee
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma; D059248:Chemoradiotherapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D015201:Meta-Analysis as Topic; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
keywords: Chemoradiotherapy; Meta-analysis; Nasopharyngeal carcinoma; Randomized trial; Therapeutic benefit